跳至主要内容
临床试验/NCT03175887
NCT03175887撤回不适用

Dorsolateral Versus Medial Prefrontal TMS for Depression

White River Junction Veterans Affairs Medical Center2 个研究点 分布在 1 个国家开始时间: 2021年9月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Depressive symptoms measured by the 17-item Hamilton Depression Rating Scale

研究概览

简要总结

This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation at the forehead versus the left side of the head for treatment of Treatment Resistant Depression.

详细描述

While transcranial magnetic stimulation (TMS) to the left dorsolateral prefrontal cortex (DLPFC) is an FDA approved treatment for depression, a growing and converging database suggests the medial prefrontal cortex (MPFC) may be even more critical to the neurobiology of depression and antidepressant treatment response. This study will compare the efficacy of high frequency transcranial madntic stimulation on these two sections of the brain.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
21 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 21-70 years old
  • inadequate response to one current antidepressant medication
  • currently depressed

排除标准

  • psychiatric comorbidities

结局指标

主要结局

Depressive symptoms measured by the 17-item Hamilton Depression Rating Scale

时间窗: Change from baseline Hamilton-17 score to follow-up visit at 1 week after final TMS intervention.

Depressive symptoms will be measured by the 17-item Hamilton Depression Rating Scale.

次要结局

未报告次要终点

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

Paul Holtzheimer

Director of Mood Disorder Services

White River Junction Veterans Affairs Medical Center

研究点 (2)

Loading locations...

相似试验

Investigational TMS Treatment for Depression | 临床试验